Gravity Analytica

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

ANGO 12.19.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-08

Name of Upcoming Event:Virtual NanoKnife Investor Event

Full Press Release SEC Filings Our ANGO Tweets

About Gravity Analytica

Recent Filings

LATHAM, N.Y.--(BUSINESS WIRE)--Dec. 19, 2024--AngioDynamics, Inc.(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open onWednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event.

Fiscal 2025 Second Quarter Financial Results Conference Call

The Company’s management will host a conference call at8:00 am ETthe same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).

This conference call will also be webcast and can be accessed from the “Investors” section of theAngioDynamicswebsite atwww.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, untilWednesday, January 15, 2025at11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13750571.

Virtual NanoKnife Investor Event

In an effort to provide investors more insight into the NanoKnife System and the Company’s strategy for the technology, the Company will be hosting a virtual investor event onJanuary 8, 2025at9:30am ET.

This event be webcast and can be accessed from the “Investors” section of theAngioDynamicswebsite atwww.angiodynamics.com.

AboutAngioDynamics, Inc.

AngioDynamicsis a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visitwww.angiodynamics.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241219061676/en/

Investors:AngioDynamics, Inc.Stephen Trowbridge, Executive Vice President & CFO(518) 795-1408

Source:AngioDynamics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com